GFP Reporter Cell Line - C1498

The prognosis for acute myeloid leukemia (AML) remains poor.Researchers have developed an AML cell membrane-encapsulated nanoparticle (AMCNP) vaccine platform in which immunostimulatory adjuvant-loaded nanoparticles are encapsulated by leukemia cell membrane material. This AMCNP vaccine strategy stimulates leukemia-specific immune responses by co-delivering membrane-associated antigens with adjuvants to antigen-presenting cells. To demonstrate that this AMCNP vaccine enhances leukemia-specific antigen presentation and T-cell responses, the researchers modified a murine-derived AML cell line to express membrane-conjugated chicken ovalbumin as a model antigen. AMCNP was efficiently uptaken by antigen-presenting cells in vitro and in vivo and stimulated antigen cross-presentation. The AMCNP vaccine significantly enhanced the expansion and effector function of antigen-specific T cells compared to the control vaccine. Prophylactic vaccination with AMCNP vaccine enhanced cellular immunity and provided protection during AML challenge. In addition, AMCNP vaccine significantly improved survival, superior to vaccination with whole leukemia cell lysates, in a post-AML remission vaccination model. In conclusion, AMCNP preserved AML-specific antigens, induced enhanced antigen-specific immune responses, and provided therapeutic benefits in AML challenge.

Figure 1. Using the GFP reporter gene cell line C1498-GFP for anti-leukemia effect studies, the researchers found significant reductions in C1498-GFP cells in the bone marrow and liver of AMCNP-vaccinated mice when re-challenged with chemotherapy and vaccination, suggesting that AMCNP vaccination enhances immune response and delays disease progression. (Johnson DT, et al., 2022)